LPL Financial
AGRX

LPL Financial’s Agile Therapeutics AGRX Stock Holding History

LPL Financial’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,230
Closed -$92.2K – 4753
2023
Q1 		$92.2K Hold
8,230
– – ﹤0.01% 4221
2022
Q4 		$93.4K Hold
8,230
– – ﹤0.01% 4186
2022
Q3 		$122K Buy
+8,230
New +$202K ﹤0.01% 4069
2022
Q2 		– Sell
-10
Closed -$4K – 4564
2022
Q1 		$4K Hold
10
– – ﹤0.01% 4172
2021
Q4 		$10K Sell
10
-3
-23% -$4.23K ﹤0.01% 4322
2021
Q3 		$25K Hold
13
– – ﹤0.01% 4278
2021
Q2 		$35K Buy
13
+1
+8% +$3.3K ﹤0.01% 4168
2021
Q1 		$52K Buy
12
+7
+140% +$37.8K ﹤0.01% 3991
2020
Q4 		$30K Sell
5
-5
-50% -$29.4K ﹤0.01% 3765
2020
Q3 		$61K Sell
10
-2
-17% -$11.5K ﹤0.01% 3421
2020
Q2 		$68K Hold
12
– – ﹤0.01% 3331
2020
Q1 		$43K Buy
+12
New +$68.9K ﹤0.01% 3096
2014
Q4 		– Sell
-5
Closed -$68K – 2815
2014
Q3 		$68K Buy
+5
New +$77.2K ﹤0.01% 2624

Other funds holding AGRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

LPL Financial's AGRX Position: Q2 2023 in Review

LPL Financial sold out of Agile Therapeutics (AGRX) in Q2 2023, closing a stake of 8,230 shares — an estimated $92.2K sold.

LPL Financial first reported a position in AGRX in Q3 2014 and held it in 13 quarters. The position peaked at $122K in Q3 2022. 16 funds tracked by Wall St. Rank hold AGRX as of Q2 2023.

  • LPL Financial reported no remaining Agile Therapeutics position as of Q2 2023 after selling out during the quarter.
  • LPL Financial sold 8,230 Agile Therapeutics shares in Q2 2023, an estimated $92.2K.
  • LPL Financial first reported a position in Agile Therapeutics in Q3 2014 and held it in 13 quarters.
  • LPL Financial's Agile Therapeutics position peaked at $122K in Q3 2022.
  • 16 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2023.

Based on LPL Financial's 13F filing for Q2 2023, filed 31 Jul 2023.